Navigation Links
Moleculin Reports Positive Data From Controlled Study of Novel Topical Psoriasis Treatment
Date:9/30/2013

HOUSTON, Sept. 30, 2013 /PRNewswire/ -- Moleculin, LLC, a clinical-stage pharmaceutical company focused on developing topical treatments for inflammatory and proliferative skin diseases, today announced positive results from a double-blind, randomized Phase 2a study with MOL4249, a novel compound in development for the treatment of psoriasis. In the study, MOL4249 was shown to be effective in the treatment of mild-to-moderate plaque psoriasis when compared to the vehicle, with no detectable side effects.

"Despite the many treatment options available today, psoriasis continues to be an underserved skin disease with need for improvements in both efficacy and long-term tolerability over available therapies," said Walter Klemp, Chairman and CEO of Moleculin. "The Phase 2 data for MOL4249 are very encouraging and support our plans for continued study in larger numbers of patients."

Study Details

The double-blind, controlled, Phase 2a study involved 16 patients with mild-to-moderate plaque psoriasis. Of these, 10 patients were treated with a topical compound containing MOL4249, while 6 were treated with a control vehicle. Patients applied the treatment twice a day for 28 consecutive days. 50% of patients treated with MOL4249 showed a 50% or better improvement in lesions, versus 17% for the vehicle. In addition, 30% of MOL4249 patients demonstrated a 75% or better improvement in lesions, versus 17% for the vehicle.

Patients and physicians reported no adverse events in the study, suggesting the potential of a topical treatment for psoriasis that is safe for long-term use. MOL4249 is a first-in-class small molecule drug that works by directly inhibiting p-STAT3, a novel target that may contribute to many chronic skin diseases regardless of its activating pathway. Data suggest that this unique mechanism of action may significantly reduce the incidence of side effects, making this co
'/>"/>

SOURCE Moleculin, LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
2. Allied Healthcare Products Reports Loss On Sales Decline
3. TPI Reports Fiscal Year 2013 Financial Results
4. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
5. Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
6. Isis Reports Follow-Up Data From ISIS-SMN Rx Phase 1 Study In Children With Spinal Muscular Atrophy
7. InspireMD Reports Fourth Quarter and Fiscal Year 2013 Results
8. Apollo Medical Holdings Reports Record Fiscal 2014 Second Quarter Results
9. Cyberonics Reports Inducement Equity Award Under NASDAQ Listing Rule 5635(c)(4)
10. Genocea Reports Positive Initial Phase 1/2a Results for GEN-003, its Pioneering Therapeutic Vaccine Candidate for the Treatment of Herpes Simplex Virus-2 (HSV-2), at ICAAC 2013
11. Omeros Reports Additional Positive Results from OMS824 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)...  PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... June 30, 2014. Quarter Ended June ... 30, 2014 increased $492,000, or 18%, to $3.2 million ... 30, 2013, due primarily to an increase of $746,000 ... Company,s largest customer, partially offset by an aggregate decrease ...
(Date:9/18/2014)... Sept. 18, 2014  Casen Buswell has a rare vascular ... harden.  His case is one of only 14 known cases ... only hospital in the United States , ... treatment with the dual wave-length laser, is Methodist Children,s Hospital, ... . Using a laser available in South ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... for innovation, increasing clinical development costs, new technologies ... fast-changing environment are important factors driving industry change. ... trial costs continue to rise due to a ... conducted by industry think tanks suggest each day ...
Breaking Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 2Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 3Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 4Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 5Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 6Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 7Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 8Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 9Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 10Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 11Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 12Pro-Dex, Inc. Announces Fiscal 2014 Fourth Quarter And Full-Year Results 13Methodist Children's Hospital In San Antonio, TX Only Hospital In The U.S. Treating Rare Vascular Condition With Dual Wave-Length Laser 2Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3
... Generex Biotechnology Corporation ( www.generex.com ) (OTC Bulletin ... peer-reviewed scientific journal Diabetes, Obesity and Metabolism ... Oral-lyn™, the Company,s proprietary buccal insulin spray product. ... subjects with impaired glucose tolerance: the prevoral study , ...
... Bionovo, Inc. (Nasdaq: BNVI ), a pharmaceutical company ... women,s health and cancer, today announced that it had received ... Clinical Guidance meeting that took place on November 8, 2010. ... overall clinical development plan. "We had a ...
Cached Medicine Technology:Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 2Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 3Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 4Generex Announces Publication of New Positive Generex Oral-lyn™ Data in Peer-Reviewed Journal 5Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 2Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 3Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 4
(Date:9/19/2014)... New York (PRWEB) September 19, 2014 ... & Game Building Platform . Earlier this month Appy Pie ... Powerful Tools for the Aspiring App Developer' by Yahoo . ... which allows people to develop beautiful applications within minutes and ... development, With advanced features and support for latest mobile operating ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, ... escalated the fight against antibiotic-resistant bacteria on Thursday, ordering ... deal with the threat. Obama signed an ... charged with crafting a national action plan for dealing ... treatable bacteria that have become resistant to standard antibiotics ...
(Date:9/19/2014)... 2014 ShopRite has launched its new ... with the 2014-2015 school year. The new program will ... eBoxTops and special donations throughout the year. , Customers ... registering their ShopRite Price Plus Card at shopriteformyschool.com can ... favorite school. By using their Price Plus Club Card ...
(Date:9/19/2014)... September 19, 2014 The Translational ... new ND® Infusion Catheter is being used ... , The study commenced on September 4th, 2014 at ... of the new catheter demonstrated a number of advancements ... stem cells. “We are at the forefront of revolutionizing ...
(Date:9/19/2014)... QueenBeeTickets.com has the largest ticket inventory that online ... set to begin on January 21 of 2015, discount John ... secure website. , Click Here to view the ... , The Plain Spoken Tour has recently been announced, and ... a show coming to their local area. Presales have been ...
Breaking Medicine News(10 mins):Health News:Business Insider Australia Rates Appy Pie as a top App & Game Building Platform 2Health News:Obama Calls for National Plan to Fight Antibiotic Resistance 2Health News:ShopRite to Donate Up to $1 Million to Local Schools 2Health News:First-in-man procedure utilizes a new method of stem cell delivery 2Health News:First-in-man procedure utilizes a new method of stem cell delivery 3Health News:John Mellencamp Plain Spoken Tour Tickets: QueenBeeTickets.com Delights Customers with Discount Tickets for Mellencamp’s 80-City 2015 Concert Tour with Carlene Carter 2
... SEATTLE, June 5 Kagome, one of Japan,s ... natural 100 percent juice,blend have been named one of ... the help of top health experts, Health Magazine put ... the ultimate test,and unveiled a total of 75 true ...
... CHAPEL HILL, N.C., June 5 Benchmarking is not ... all economic climates. This research,excerpt presents a survey analysis ... companies on how companies are using benchmarking in a,difficult ... hot topics companies are,choosing to benchmark, the goals of ...
... brain chemical serotonin influences fat metabolism , , THURSDAY, June ... is a frustrating truism familiar to the diet-conscious choosing ... that weight control isn,t just a matter of what ... nervous system is genetically predisposed to process fat. , ...
... Presented by The Massachusetts School of,Professional Psychology, ... in this state about the ,invisible wounds of ... the stress, depression and post traumatic,stress disorder (PTSD) ... of,domestic violence and suicide. We need to begin ...
... Army Corps of,Engineers, in partnership with federal, state ... partners, will,participate in the first National Get Outdoors ... more than 75 organizations will conduct hundreds of,outdoor ... the country according to event co-sponsors, the U.S. ...
... of free health information, giveaways, entertainment and ... ... bodybuilder Chad,Gregory, along with professional fitness and figure competitors Allison,Frahn and Tina ... weekend at the Cobb Galleria Centre in Atlanta., Chad, part of ...
Cached Medicine News:Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 2Health News:Kagome's Yellow Mango Orchard Blended Juice Named One of America's Healthiest Buys 3Health News:Demonstrating the Value of Benchmarking in an Uncertain Economy 2Health News:Weight Gain May Not Be Based Just on What You Eat 2Health News:Weight Gain May Not Be Based Just on What You Eat 3Health News:Growing Public Health Crisis of Domestic Violence and Suicides by Returning Veterans 2Health News:Army Corps of Engineers Will Host National Get Outdoors Day Activities at Six Corps Project Sites 2Health News:Rite Aid Health and Beauty Expo to Showcase GNC Athletes 2
... The Akbarnia PDR Instruments ... surgeons negotiate in and around ... and reconstruction procedures. The instruments ... construction, a variety of angled ...
... is a point-of-care system designed for the ... to as Platelet Rich Plasma - PRP) ... small sample of blood. The Symphony II ... which are found in the platelets. The ...
... the introduction of the Leica Dual Imaging Color ... latest available information technology. All important and necessary ... Leica M520 / M500 N optical platform on ... a huge amount of benefits: highest brightness, contrast ...
... Headlight mounted micro video camera has been ... in areas otherwise invisible to all but ... The system may be used for all ... crowding of the sterile area and enabling ...
Medicine Products: